Ovid Therapeutics Inc. (OVID)

Market Cap	181.52M
Revenue (ttm)	1.50M
Net Income (ttm)	-54.17M
Shares Out	70.49M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	1.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,066
Open	2.70
Previous Close	2.70
Day's Range	2.53 - 2.74
52-Week Range	1.41 - 3.35
Beta	1.10
Analysts	Buy
Price Target	4.85 (+87.26%)
Earnings Date	May 8, 2023

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID

Analyst Forecast

According to 10 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $4.85, which is an increase of 87.26% from the latest price.

Price Target

$4.85

(87.26% upside)

Analyst Consensus: Buy